Source comparison
CJC-1295 no DAC & Ipamorelin vs Other Fat Loss Peptides
The peptide landscape for body recomposition includes multiple mechanisms. GH secretagogues, GLP-1 agonists, melanocortin receptor agonists, and mitochondrial uncouplers. Each operates through distinct pathways with different risk-benefit profiles and research
This comparison does not assign a generated winner or score.
- The peptide landscape for body recomposition includes multiple mechanisms. GH secretagogues, GLP-1 agonists, melanocortin receptor agonists, and mitochondrial uncouplers. Each operates through distinct pathways with different risk-benefit profiles and research applications.
- CJC-1295 no DAC & Ipamorelin
- GHRH analog + GHS receptor agonist
- GH-mediated lipolysis via HSL activation; preserves lean mass
- 30 min (CJC), 2 hours (Ipa)
- 100–200 mcg each, 1–3× daily
- Best synergy for fat loss with muscle retention; requires consistent dosing and proper meal timing
- Tesamorelin Ipamorelin
- GHRH analog + GHS (alternative GHRH)
- GH secretion; specifically studied for visceral adipose reduction
- 50 min (Tesa), 2 hours (Ipa)
- 1–2 mg Tesa + 200 mcg Ipa daily
- Superior for visceral fat; Tesamorelin has specific research in HIV lipodystrophy; higher cost
- AOD9604
- Modified GH fragment (hGH 176-191)
- Lipolysis without GH receptor activation; no IGF-1 elevation
- 30–60 min
- 250–500 mcg daily, fasted
- Lipolytic effect without systemic GH exposure; no insulin resistance risk; less lean mass retention
- Semaglutide (GLP-1)
- GLP-1 receptor agonist
- Appetite suppression + delayed gastric emptying
- 5–7 days
- 0.25–2.4 mg weekly
- Highest magnitude weight loss (15–20%); mechanism is caloric restriction, not lipolysis; muscle loss common
- Tesofensine
- Triple monoamine reuptake inhibitor
- CNS-mediated appetite suppression + thermogenesis
- 8 days
- 0.25–1 mg daily
- Potent appetite suppression; cardiovascular monitoring required; not a peptide (small molecule)
- Melanotan II
- MC4R agonist
- Appetite suppression + possible thermogenic effect
- 33 min
- 250–500 mcg daily
- Appetite effect inconsistent; primarily used for tanning; nausea common
- CJC-1295 no DAC & Ipamorelin for fat loss sits in a distinct category: it enhances fat oxidation without requiring caloric restriction to work, though the effect amplifies significantly when combined with an energy deficit. GLP-1 agonists like semaglutide produce larger total weight loss but through a fundamentally different mechanism. Reduced food intake leading to weight loss, not direct metabolic action on adipocytes. That distinction matters for body composition: GLP-1 users commonly lose 25–35% of total weight as lean mass unless they implement aggressive protein intake and resistance training, while CJC-1295 no DAC & Ipamorelin users typically maintain or gain lean mass during fat loss phases.
- AOD9604 offers pure lipolytic action without any growth hormone receptor activation, which eliminates the insulin resistance and joint discomfort some users experience with full GH elevation. However, it also eliminates the lean mass preservation and recovery benefits that make CJC-1295 no DAC & Ipamorelin attractive for body recomposition rather than weight loss alone. Tesamorelin has the strongest research backing for visceral adipose reduction specifically, with FDA approval for lipodystrophy treatment, but comes at a significantly higher cost than CJC-1295 combinations.
- Our team has reviewed research applications across hundreds of peptide protocols in this category. The pattern is consistent: CJC-1295 no DAC & Ipamorelin for fat loss produces moderate fat reduction (0.5–1% body fat per month) with simultaneous lean mass preservation or gain, making it ideal for body recomposition phases. Pure weight loss magnitude favors GLP-1 agonists. Pure muscle retention favors standalone MK 677 (a non-peptide GHS with 24-hour half-life). The CJC/Ipa combination balances both.